Investor Notice: Robbins LLP Informs Investors of Class Action Filed Against bluebird bio, Inc. (BLUE)
March 30, 2024 01:44 ET
|
Robbins LLP
Robbins LLP is Investigating the Allegations that Bluebird Bio, Inc. (BLUE) Overstated the Clinical and/or Commercial Prospects of its Drug
Infinity Pharmaceuticals, Inc. (INFI) Shareholder Notice: Robbins LLP Reminds Investors of Class Action Filed Against Infinity Pharmaceuticals, Inc.
August 21, 2023 12:35 ET
|
Robbins LLP
SAN DIEGO, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of persons and entities that purchased or otherwise acquired Infinity...
ALDX Investor Alert: Robbins LLP Urges Investors to Contact the Firm for Information about the Upcoming Lead Plaintiff Deadline in Aldeyra Therapeutics, Inc. Class Action Lawsuit
August 17, 2023 15:59 ET
|
Robbins LLP
SAN DIEGO, Aug. 17, 2023 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of investors who purchased or otherwise acquired Aldeyra (NASDAQ: ALDX)...
APLS Stock News: Investors with Significant Losses in Apellis Pharmaceuticals, Inc. Should Contact Robbins LLP About Recovery
August 14, 2023 18:01 ET
|
Robbins LLP
SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action against Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) on behalf of persons or...
ALDX Stock News: Shareholders with Significant Losses in Aldeyra Therapeutics, Inc. Should Contact Robbins LLP
August 11, 2023 15:11 ET
|
Robbins LLP
SAN DIEGO, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of investors who purchased or otherwise acquired Aldeyra (NASDAQ: ALDX)...
BioXcel Therapeutics, Inc. (BTAI) Sued by Shareholders: BTAI Investors Should Contact Robbins LLP for Information About Their Rights
July 20, 2023 14:53 ET
|
Robbins LLP
SAN DIEGO, July 20, 2023 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired BioXcel...
Biothera Pharmaceuticals Commences Phase 2 Head and Neck Cancer Study Evaluating Combination of Imprime PGG and Merck’s KEYTRUDA® (pembrolizumab)
February 06, 2018 09:30 ET
|
Biothera Pharmaceuticals, Inc.
EAGAN, Minn., Feb. 06, 2018 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. announced today that patient treatment has commenced in its Phase 2 clinical study in squamous cell carcinoma of the...
Biothera Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Study Evaluating Combination of Imprime PGG and Merck’s KEYTRUDA in Non-Small Cell Lung Cancer
July 19, 2017 10:00 ET
|
Biothera Pharmaceuticals, Inc.
EAGAN, Minn., July 19, 2017 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. today announced that the Big Ten Cancer Research Consortium has begun patient dosing in a Phase 1b/2 clinical study to...
Biothera Pharmaceuticals Announces Presentation at the Upcoming 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
May 31, 2017 09:00 ET
|
Biothera Pharmaceuticals, Inc.
EAGAN, Minn., May 31, 2017 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. announced today that a poster about the design of IMPRIME-1™, the company’s ongoing Phase 2 clinical trial in advanced...